ArticleHeliyon2024
Erythema nodosum as first clinical manifestation of metastatic neuroendocrine tumor: A case report.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythema nodosum (EN) is a reactive inflammatory panniculitis, which has been associated with medications, infections, autoimmune and autoinflammatory diseases. It has rarely been associated with neoplasms. We present the case of a 61-year old woman who was admitted because 3-week history of painful erythematous subcutaneous nodules on the lower limbs clinically consistent with EN, which was confirmed by skin biopsy. The patient denied use of medication. No general or systemic symptoms were present. As part of his study, an abdominal ultrasound and later magnetic resonance imaging (MRI) was done and lesions suggestive of liver metastases were reported. An ultrasound guided liver biopsy was then performed and pathology studies evidence a well differentiated grade II gastro-enteropancreatic neuroendocrine tumor (GEP-NET). A 9mTc-Octreotide scintigraphy evidenced a positive expression of somatostatin receptor in the liver and in a nodular mesenteric lesion in contact with an intestinal loop. The patient began treatment with lanreotide and was scheduled for cytoreductive surgery. During surgery, 50 cm of the small intestine, gallbladder, mesenteric fat and a 4.2x3.3 × 1 cm tumor located on the VII hepatic lobe were resected. Subsequently EN lesions of the lower extremities resolved. We present a rare case of GEP-NET-associated EN, that improved with surgical tumor cytoreduction and hormone therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.